Sequenom COmpletes FDA Collaboration On MassArray
SAN DIEGO -(Dow Jones)- Sequenom Inc. (SQNM) completed a collaboration with the Food and Drug Administration resulting in a faster method for analysis of viruses and quality control of large-scale vaccine protection.
Sequenom, the FDA and Aventis Pasteur, demonstrated the use of MassArray technology to accelerate and improve the accuracy of live virus analysis.
In a press release Thursday, Sequenom, a discovery genetics company, said applications include improved quality control of existing viral vaccines, greater genetic understanding of RNA viruses for the development of new diagnostics and identification of specific viral strains that could help narrow an investigation of its origin to specific laboratories.
The FDA said that with the advancements presented by the MassArray technology, there is the potential to develop improved vaccines at a much faster rate.
The MassArray enables identification of specific strains of complex populations of viruses with greater speed and accuracy than in the past.
Results of the collaborations were published in a recent edition of the Proceedings of the National Academy of Sciences.
|aus der Diskussion:||Sequenom: Super Chance in nächster Zeit!!! Wie ist eure Meinung?|
|Autor (Datum des Eintrages):||bigguru (30.10.01 18:33:14)|
|Beitrag:||21 von 66 (ID:4757326)|
|Alle Angaben ohne Gewähr © wallstreet:online|